Last Updated on October 2, 2024 by The Health Master
Benralizumab
Good news for severe asthma sufferers in India! AstraZeneca Pharma’s Benralizumab solution for Injection 30 mg/ml in auto-injector has been granted conditional approval by the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO).
This innovative treatment offers a convenient and potentially life-changing option for patients with a specific type of severe asthma.
What is Benralizumab and How Does it Work?
Severe eosinophilic asthma is a debilitating form of asthma characterized by high levels of eosinophils, a type of white blood cell.
Benralizumab is a monoclonal antibody, a highly targeted therapy designed to treat this specific type of asthma.
It works by binding to the interleukin-5 receptor (IL-5R) on eosinophils, effectively blocking the signals that cause inflammation in the airways.
Benefits of the Auto-Injector Delivery System
The auto-injector provides a convenient and user-friendly way for patients to administer their Benralizumab medication at home.
This eliminates the need for injections in a clinical setting, potentially improving adherence to treatment and overall patient experience.
Conditional Approval and Phase IV Trial
The SEC granted approval with a waiver for the local Phase III clinical trial.
This means that the drug’s safety and efficacy have already been established in global trials, but AstraZeneca must conduct a Phase IV clinical trial specifically focused on the Indian population.
This Phase IV trial will generate data on the medication’s safety, functionality, and reliability of the auto-injector in the Indian context.
Key Takeaways:
- Benralizumab auto-injector offers a promising treatment option for severe eosinophilic asthma in India.
- The auto-injector provides a convenient and potentially empowering way for patients to manage their condition.
- Conditional approval allows access to the medication while ensuring data collection specific to the Indian population.
What This Means for Patients
This approval represents a significant step forward in the management of severe eosinophilic asthma in India.
Patients with this specific type of asthma may now have access to a potentially life-changing treatment option.
The auto-injector delivery system offers increased convenience and potentially improved treatment adherence.
However, it’s important to consult with a healthcare professional to determine if Benralizumab is the right treatment for you.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
CDSCO: Updated version of guidance document for Biologicals
CDSCO underscores stringent compliance to Revised Schedule M
CDSCO Committee to Revise Rule 64 for drug sales in India
Relief for Medical Devices: CDSCO Grants 3-Month Extension
CDSCO: Timely pay retention fee to Avoid Disruption in Medical Device licenses
CDSCO approval granted for the drug to treat GPP
BIS Standards for Medical Device Testing in India
NABL Clarifies Test Method for Blood-Resistant PPE
Govt issues instructions on marketing codes of pharma companies
Nutraceuticals in Drug Units: Panel to examine the issue
CDSCO underscores stringent compliance to Revised Schedule M
USFDA issues OAI status to Eugia Pharma of Aurobindo
Can Your Air Handling Meet the new Schedule M? Find Out Here
New R&D Policy Ushers in Era of Collaboration and Efficiency
Govt Job: For Pharmacists under Public Service Commission
FSSAI warns against sale of human milk and its products in India
